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ess under CC BY-NC-Abstract In this work, retinal penetration of ﬂuorescein was achieved in vitro by covalent attachment of
taurine to ﬂuorescein, yielding the F–Tau conjugate. Nuclear magnetic resonance (NMR) and high
resolution mass spectrometry (HRMS) were used to conﬁrm the successful synthesis of F–Tau. The
cellular uptake of F–Tau in adult retinal pigment epithelial cells (ARPE-19) and human retinal
microvascular endothelial cells (hRMECs) was visualized via confocal scanning microscopy. The results
indicated an improvement of solubility and a reduction of logP of F–Tau compared with ﬂuorescein. As
compared with ﬂuorescein, F–Tau showed little toxicity, and was retained longer by cells in uptake
experiments. F–Tau also displayed higher transepithelial permeabilities than ﬂuorescein in ARPE-19 and
hRMECs monolayer cells (Po0.05). These results showed that taurine may be a useful ligand for
targeting small-molecule hydrophobic pharmaceuticals into the retina.
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Retinal diseases, such as retinal neuronal injury, age-related
macular degeneration and cytomegalovirus retinitis, are important
causes of blindness; yet the present medications for the treatment
of retinal diseases are not ideal1,2. Topically-applied medications
(drops) do not achieve the effective drug concentration in the
retina due to the presence of corneal barriers. Local (e.g.,
intravitreal) injections are invasive, and can result in retinal
detachment and endophthalmitis after repeated injections3,4.
Although the extensive vascularization of the posterior of the
eye might seem to predict favorable retinal penetration of
systemically-administered drugs, the existing blood–retinal barrier
(BRB) limits drug diffusion from blood to the retina. Thus, better
methods are needed to facilitate the penetratration of the BRB
following systemic administration of drugs for retinal diseases.
The BRB is composed of two parts, each providing some barrier
functions5. The outer barrier (oBRB) contains the retinal pigment
epithelium (RPE) which is located between the choroid and the neural
retina. Under normal circumstances, RPE cells are tightly arranged and
closely connected to the outer layer of the neural retina, providing an
effective barrier between the neural retina and peripheral tissues.
Exogenous substances do not easily enter the retina by penetrating
the oBRB except for nutrients needed to maintain normal physiological
functions. Some nutrients are selectively transported into the retinal
layers by the RPE cells6. The second component of the BRB, the inner
barrier (iBRB), is formed by the tightly-arranged retinal microvascular
endothelial cells (RMECs) located within the vascular lumen. The
iBRB isolates the retinal tissue from blood, thereby maintaining the
stability of the neural retina by restricting the entry of toxic molecules,
plasma, and water into the retina6,7. These components of the BRB
explain why exogenous drugs have difﬁculty in penetrating the retina
following systemic administration.
Taurine, an endogenous β-aminosulfonic acid, is important for
cardiovascular, skeletal muscle and retinal health. Although taurine
can be biochemically synthesized from cysteine in the liver8, this
pathway is not sufﬁcient, resulting in a need for dietary taurine.
Children may suffer from visual dysfunction during dietary taurine
deﬁciency; this may be reversed by taurine supplements9. Exogen-
ous taurine was reported to be actively transported by a taurine
transporter (TauT) into cells10–12. As for the retina, taurine can be
considered as an essential component in the development and
maintenance of retinal form and function. The occurrence of
retinitis, retinal degeneration, diabetic retinopathy and vision loss
are closely related to the deﬁciency of taurine12–14.
The physiological signiﬁcance of taurine in the retina may be
emphasized by the high levels of retinal taurine. Heinamaki et al.15
reported that taurine is the most abundant free amino acid in the
retina (12 μmol/g retinaE12 mmol/L in rats), accounting for more
than 50% of the free amino acid content11. In addition, the taurine
concentration in the retina is about 100-fold greater than that in the
serum (100–300 μmol/L)16. Such high levels of taurine may
suggest powerful mechanisms for its accumulation in the retina.
However, the retina-targeting ability of taurine is still unknown;
therefore it is meaningful to investigate whether the taurine can be
used as a tool to improve penetration of the BRB by exogenous
drugs following systemic administration.
Based on the hypothesis described above, we ﬁrstly synthesized a
taurine-conjugated ﬂuorescein (F–Tau) by covalently attaching taurine
to ﬂuorescein. We then investigated the BRB-penetrating ability of
F–Tau in two assembled monolayers of adult retina pigment epithelial
cells (ARPE-19) and human retinal microvascular endothelial cells(hRMECs), two cell lines expressing TauT17,18. These experiments
have investigated the retina-targeting potential of taurine.2. Materials and methods
2.1. Materials and cells
Taurine (purity 98%) was purchased from TCI (Shanghai, China).
Other reagents and solvents (analytical grade) from Aladdin (Shanghai,
China) were used without further puriﬁcation unless otherwise
indicated. Silica gel (GF254, 300–400 mesh) based thin-layer chroma-
tography was used to monitor the processes of reactions. NMR spectra
were measured on a Bruker Avance III 400 MHz spectrometer.
Chemical shifts were recorded in parts per million (ppm) using
tetramethylsilane as an internal standard in dimethyl sulfoxide-d6
(DMSO-d6). Electrospray ionization-mass spectrometry (ESI-MS)
was used to acquire the mass spectra on a TSQ Quantum Access
Max (Thermo Scientiﬁc, San Jose, CA, USA). High resolution mass
spectra (HRMS) of F–Tau were recorded using an Agilent Accurate-
Mass-Q-TOF MS 6520 system under positive ionization mode. High-
performance liquid chromatography (HPLC, Agilent 1200, USA) was
performed to determine the purity of the compounds described in this
paper. The purity of F–Tau was found to be higher than 95%.
ARPE-19 were kindly donated by Zhongshan Ophthalmic
Center of Sun Yat-Sen University and hRMECs were bought
from Guangzhou Jennio Biotech Co., Ltd. The cells were
respectively cultured in Dulbecco's Modiﬁed Eagle media: nutrient
mixture F-12 (DMEM/F12) and roswell park memorial institute
1640 (RPMI 1640) (Invitrogen, Grand Island, NY, USA) contain-
ing 10% fetal bovine serum, 1% penicillin (50 IU/mL) and
streptomycin (50 μg/mL) in an atmosphere of 5% CO2 at 37 1C.
2.2. Chemistry
2.2.1. The synthesis of the intermediate active ester (3)
Fluorescein 1 (3.32 g, 10 mmol), N-hydroxysuccinimide 2 (1.17 g,
10 mmol) and dicyclohexylcarbodiimide (DCC, 2.10 g, 10 mmol)
in anhydrous dimethylformamide (DMF) were heated to 75 1C
under nitrogen for 1.5 h. The resulting dicyclohexylurea (DCU)
was ﬁltered off at 0 1C and the solvent was evaporated under
rotary evaporator at reduced pressure19. Then the crude residue
was puriﬁed by silica column (Petroleum ether/Acetone, 3:1-1:1,
v/v) to afford active ester 3 as red-orange solid, yielding 1.29 g
(30%). 1H NMR (400 MHz, DMSO-d6): δ 11.07(s, 1H), 8.36(d,
J¼8 Hz, 1H), 8.03(t, J¼4 Hz, 1 H), 7.90(t, J¼4 Hz, 1 H), 7.66(d,
J¼8 Hz, 1H), 6.99–6.23(m, 6H), 2.72(s, 4H). MS (ESI): m/z
428.1 [M–H] (Supplementary Figs. 1 and 2).
2.2.2. The synthesis of F–Tau (5)
The active ester 3 (1.00 g, 2.33 mmol) was dissolved in anhydrous
DMF, to which taurine 4 (0.58 g, 4.66 mmol) and 0.65 mL of
triethylamine (Et3N, 4.66 mmol) that previously dried out under
molecular screen cleaner were added. The obtained mixture was
stirred at room temperature (RT) for 36 h and evaporated under
rotary evaporator connected to a high vacuum. The crude residue
was sequentially puriﬁed by silica column (ethyl acetate/ metha-
nol, 4:1, v/v), ODS (octadecyl silane) column chromatography
(methanol/H2O) and preparative HPLC (acetonitrile/formic acid
buffer) to afford the desired product F–Tau (5) as white powder,
yielding 0.42 g (41%). 1H NMR (400 MHz, DMSO-d6):δ 8.34(br,
1 H), 7.79(dd, J¼4 Hz, 1H), 7.49(m, 2H), 6.98(dd, J¼4 Hz, 1H),
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2H), 3.26(t, J¼8 Hz, 2H), 2.17(t, J¼8 Hz, 2H); 13C NMR
(101 MHz, DMSO-d6): δ166.71, 158.43 (2C), 153.30, 151.90
(2C), 132.56, 129.98, 128.56 (2C), 128.42, 123.51, 122.49,
112.07 (2C), 109.32 (2C), 102.39 (2C), 63.37, 49.18, 36.71;
HRMS (ESI-TOFþ): m/z calcd. for C22H17NO7S: 440.0798;
found: 440.0796 [MþH]þ (Supplementary Figs. 3–5).
2.3. Solubility studies
Saturated ﬂuorescein and F–Tau solutions were obtained by dissolving
excess ﬂuorescein and F–Tau in doubly distilled water (2 mL) in
centrifugal tubes respectively. Then the centrifugal tubes were shaken
at 100 times/min at 25 1C for 24 h. After further still standing for 24 h
at 25 1C, the saturated solutions were centrifuged and 20 μL of
supernatant was injected into HPLC as described below (Section 2.7.4).
2.4. Estimation of logP
To determine the n-octanol/water partition coefﬁcients of ﬂuor-
escein and F–Tau, the traditional saturation shake ﬂask methods
were performed. After 24 h shaking of a conical ﬂask containing
n-octanol (30 mL) and double-distilled water (30 mL) at
100 times/min, n-octanol-saturated water and water-saturated n-
octanol were obtained by centrifugation of the mixture at
4000 rpm for 10 min. Subsequently, ﬂuorescein and F–Tau were
dissolved in water-saturated n-octanol (2 mL), respectively. After
adding 2 mL of n-octanol-saturated water, the mixture was shaken
at 100 times/min at 25 1C for 24 h, centrifuged at 4000 rpm for
10 min and separated to obtain aqueous phases and oil phases.
After proper dilution, 20 μL of aqueous phases or oil phases were
injected into HPLC as described below (Section 2.7.4).
The partition coefﬁcients (P) were calculated using the follow-
ing equation:
P¼C0=Cw ð1Þ
where C0 means the drug concentration of oil phases and Cw
represents the drug concentration of water phases.
2.5. MTT cytotoxicity assay
The cytotoxicities of ﬂuorescein and F–Tau were assayed on
ARPE-19 and hRMECs using the (3,4,5-dimethylthiazol-yl)-2,5-
diphenyl-tetrazolium (MTT) assay. Brieﬂy, ARPE-19 and
hRMECs were seeded in 96-well plates at a density of 1 105
cells/well and cultured for 24 h at 37 1C. Then the cells were
treated with different concentrations of ﬂuorescein and F–Tau for
24 h followed by incubation with MTT (10 μL) (5.0 mg/μL,
Sigma-Aldrich, St. Louis, MO, USA) for 4 h at 37 1C. Finally,
the medium was replaced with 100 mL dimethyl sulfoxide
(DMSO), and the optical density (OD) was determined with a
microplate reader at a wavelength of 490 nm in triplicate. The cells
viability was calculated using the following equation:
Cells viability %ð Þ ¼ A490 nm Treated cells=A490 nm Control cells  100 ð2Þ
2.6. Cellular internalization
ARPE-19 and hRMECs, both expressing taurine transporter, were used
for the cell internalization study. ARPE-19 and hRMECs wereindividually seeded on confocal dishes at a density of 5 103 cells/
well and incubated for 24 h at 37 1C; then 100 μmol/L ﬂuorescein and
100 μmol/L F–Tau were added to these cells and co-incubated for
another 2 h and 6 h. The cells were washed for three times with Hank's
balanced salt solution (HBSS, Ji Nuo Biology Co., Guangxi, China.)
and the a Zeiss LSM 710 laser scanning confocal microscope (Carl
Zeiss Meditec AG, Jena, Germany) was used to investigate the
intracellular uptake (excitation wavelength for ﬂuorescein: 488 nm,
excitation wavelength for F–Tau: 405 nm).2.7. Transport studies of ﬂuorescein and F–Tau across
monolayer cells in vitro
2.7.1. Transport studies of ﬂuorescein and F–Tau across ARPE-
19 monolayer cells20,21
Transport studies of ﬂuorescein and F–Tau to pass through ARPE-
19 monolayer cells were performed on 12-well plates containing
Transwells inserts with 0.4 μm pore size polycarbonate membrane
(Corning Costar, Corning, NY, USA). Brieﬂy, ARPE-19 were
trypsinized, resuspended and seeded in the upper chamber at a
density of 2.5 105 cells/well in 0.5 mL medium as well as
1.5 mL blank medium added in the lower chamber. Then the
culture medium was replaced [0.5 mL in the apical (AP) side and
1.5 mL in the basolateral (BL) side] every other day for the ﬁrst
week and everyday after the ﬁrst week. And when the transe-
pithelial electrical resistance (TEER, Evom Epithelial Volt-ohm-
meter, Sarasota, FL, USA) of the monolayer cells reached 150 Ω,
the monolayer cells were employed in the transport studies22,23.
Before transport experiments, the culture medium was removed
and the monolayer cells were rinsed twice with preheated HBSS
solution. Right before ARPE-19 transport studies, 0.5 mL pre-
heated (37 1C) HBSS solution containing 100 μmol/L ﬂuorescein
or 100 μmol/L F–Tau was added to the AP side, while 1.5 mL
preheated (37 1C) blank HBSS solution was loaded in the BL side.
And then these plates were put in the atmosphere in 5% CO2/
37 1C. At indicated time intervals (30, 60, 120, 240 and 360 min),
100 μL of samples were taken from the receiver sides and
immediately replaced with 100 μL fresh preheated blank HBSS
solution. The TEER values of the monolayer maintained at about
150 Ω in the above processes. Those obtained samples were
determined by HPLC as mentioned below (Section 2.7.4).
Apparent permeability coefﬁcients (Papp) values were calculated
using the equation:
Papp ¼ ΔQ=Δt
 
= A C0ð Þ ð3Þ
where ΔQ/Δt is the linear appearance rate of mass in BP side, A is
the ﬁlter/cell surface area (1.12 cm2 for 12-well and 0.33 cm2 for
24-well), and C0 is the initial concentration of the test compounds.2.7.2. Transport studies of ﬂuorescein and F–Tau across
hRMECs monolayer cells
Transport studies of ﬂuorescein and F–Tau in hRMECs monolayer
cells were performed on 24-well plates containing Transwells
inserts with 0.4 μm pore size polycarbonate membrane (Corning
Costar, Corning, NY, USA). The general procedure for the
transport studies of ﬂuorescein and F–Tau across hRMECs
monolayer cells was similar to that of ARPE-19 except the
supplied medium was 0.15 mL to the AP side and 0.6 mL to the
BP side. And the transport studies could be initiated when the
TEER reached 200 Ω24,25.
Scheme 1 Synthesis of F–Tau.
Table 1 Solubility and logP of ﬂuorescein and F–Tau.
Sample Solubility (μg/mL) log P
Fluorescein 6.75 1.55
F–Tau 10,852.54 1.03
Scheme 2 The interconversion of ﬂuorescein.
Figure 1 The survival rate (%) of hRMECs (A) and ARPE-19 (B)
after incubated with ﬂuorescein and F–Tau at various concentrations
for 24 h (n¼6). Data are presented as mean7SD.
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medium in Transwells inserts was removed and rinsed twice.
And in hRMECs transport studies, preheated HBSS solution
containing ﬂuorescein or F–Tau (100 μmol/L, 0.15 mL) was
added to the AP side while 0.6 mL of preheated blank HBSS
solution loaded in the BL side. Also, at indicated time intervals
(30, 60, 120, 240 and 360 min), 60 μL of samples were taken
from the receiver sides and immediately replaced with 60 μL
fresh preheated blank HBSS solution. The TEER values of the
monolayer were still about 200 Ω in the above processes. Those
obtained samples were determined by HPLC as mentioned
below (Section 2.7.4).
2.7.3. Competition assay of transport studies
Free taurine was used as a competitive inhibitor to study whether
the transportation of F–Tau was mediated via the TauT. ARPE-19
and hRMECs monolayer cells were prepared as described above.
Before the transport studies, preheated HBSS solution containing
taurine (10 mmol/L) was added to both the upper and lower
chambers and incubated for 24 h in 5% CO2 at 37 1C. Then the
competitive transport experiments of the two monolayer cells were
proceeded as the transport studies described above. Those obtained
samples were also determined by HPLC as mentioned below
(Section 2.7.4).
2.7.4. HPLC analysis
The concentrations of ﬂuorescein and F–Tau in the samples were
analyzed by HPLC (Agilent 1200, USA) with Phenomenex
Synergi Polar-RP (250 mm 4.6 mm, 4 μm) at 35 1C. The ultra-
violet detecting wavelength was set at 230 nm, and the injection
volume was 20 μL. The mobile phase, consisting of phosphate
buffer solution at pH 2.5 (phase A) and acetonitrile (phase B), wasdelivered at a ﬂow rate of 1.0 mL/min. The isocratic elution
method (50:50, v/v) was used to analyze ﬂuorescein in 12 min.
And the gradient elution method was used to analyze F–Tau by
varing the percentages of phase A and phase B from 70:30 to
58:42 in 15 min.2.8. Data analysis
Data were expressed as means7standard deviation (SD). Statis-
tical signiﬁcance of the difference was assessed by one-way
analysis of variance to determine the signiﬁcance among groups
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P value o0.05 was considered signiﬁcant.3. Results and discussion
3.1. Synthetic routes
The synthetic pathway for F–Tau is illustrated in Scheme 1.
Traditionally, ﬂuorescein has been viewed to exist in two forms
(Scheme 2): a highly ﬂuorescent, open, quinone form and a non-
ﬂuorescent, closed, spirolactone form26. In order to obtain F–Tau,
the ﬁrst step involved the activation of ﬂuorescein because it was
difﬁcult to react with primary amines like taurine when the
carboxyl group was masked. After ﬂuorescein was activated to
the open form by reacting with N-hydroxysuccinimide (which has
a good leaving group), taurine could react rapidly with this active
ester in DMF under alkaline condition at ambient temperature.
Surprisingly, we found the intensely red-orange active ester
solution was converted into a nearly colorless solution after the
reaction and the non-ﬂuorescent white solid (F–Tau) was isolated
by preparative HPLC. The resulting F–Tau was in a closed, spiro-
lactam form, consistent with the results of Adamczyk and Grote26.
This conﬁguration was conﬁrmed by the characteristic spirolactam
peak near 64 ppm in the 13C NMR spectrum (Supplementary
Fig. 4)26. After intravenous injection, this closed-spirolactam form
of F–Tau was expected to be opened by lactamase, resulting in an
open form of taurine conjugate exposing the effective structure of
taurine. The newly-formed taurine conjugate would then be speciﬁ-
cally recognized and actively transported by the taurine transporter,
resulting is penetration of the BRB.Figure 2 Confocal scanning microscopy images of APRE-19 (A) and hR
F–Tau (AT and hT). The number on the right side of the alphabet was
ﬂuorescein. Blue: ﬂuorescence of F–Tau.3.2. Physicochemical properties of F–Tau
As shown in Table 1, the solubility of F–Tau increased nearly
1600-fold compared with ﬂuorescein due to the presence of polar
sulfonic acid group. The latter facilitates F–Tau's initial water
solubility. In addition, the partition coefﬁcient of F–Tau was
sharply reduced as compared with that of ﬂuorescein, decreasing
from the original 1.55 to 1.03 (Table 1). As compared with
highly lipophilic drugs, this reduction in log P value might be
beneﬁcial in reducing drug efﬂux from the cells, thereby extending
residence time in the cell. Above all, the introduction of taurine
might enhance the exposure dose and exposure time of ﬂuorescein
in vivo, thereby improving the efﬁcacy of the drug.
3.3. Cytotoxicity
To screen the appropriate concentration of F–Tau for transport
experiments on ARPE-19 and hRMECs monolayer cells, the survival
rates of the two cells exposed to various concentrations of F–Tau were
measured by the MTT assay (Fig. 1). At dose levels of 0–200 μmol/L
F–Tau showed no toxicity on hRMECs (Fig. 1A) and even exhibited a
slight promotion of growth for ARPE-19 (Fig. 1B). Thus, taurine can
be safely used as a ligand in these studies. Incorporating the limit of
detection of the HPLC and the condition of cells into account, a
concentration of 100 μmol/L F–Tau and ﬂuorescein was used in the
following studies.
3.4. Cellular uptake assay
As shown in Fig. 2, strong ﬂuorescence was observed in ARPE-19
(AF2 and AT2) and hRMECs (hF2 and hT2) after treatment withMECs cells (h) incubated with free ﬂuorescein (AF and hF) and free
represented for the incubated time at 37 1C. Green: ﬂuorescence of
Figure 3 The time proﬁles of transport experiment across ARPE-19
(A) and hRMECs (B) monolayer (n¼3). *Po0.05, **Po0.01, *F–
Tau versus ﬂuorescein. △Po0.05, △△Po0.01, △△△Po0.001, △F–
TauþTau versus ﬂuorescein.
Table 2 Effect of taurine on Papp values of F–Tau across
ARPE-19 and hRMECs monolayer cells.
Test drug Papp ( 106 cm/s) Ratio(Papp, Test Drug-to-
Fluoresein)
ARPE-19 hRMECs ARPE-19 hRMECs
Tau 7.7271.13 10.6770.36 1.39 1.47
F–TauþTau 7.7971.01 13.3070.91 1.40 1.84
Fluorescein 5.5670.80 7.2370.92 – –
Tau is presented as taurine. Papp values are presented as mean7SD
(n¼3).
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ﬂuorescein and F–Tau could be internalized by the two kinds of
cells. Interestingly, after 6 h incubation, almost no ﬂuorescein was
observed in the ﬂuorescein groups (AF6 and hF6), whereas
ﬂuorescence was still seen in the F–Tau groups (AT6 and hT6)
in both cell lines. The high lipophilicity of ﬂuorescein may make iteasy to be internalized by the cells within 2 h at ﬁrst and be
inclined to be excluded during the next 4 h by the same reason.
Meanwhile the lower log P value of F–Tau was thought to reduce
the probability of efﬂux, yielding weak ﬂuorescence 6 h after
incubation. These results showed that incorporation of taurine
extends the retention time of ﬂuorescein in the retina cells.3.5. Transportation of ﬂuorescein and F–Tau across the
monolayer cells in vitro
To determine the transepithelial permeability of ﬂuorescein and
F–Tau, the transport studies were carried out on ARPE-19
(Fig. 3A) and hRMECs (Fig. 3B) monolayer cells in transwells
inserts. The two monolayer cells were established to serve as the
permeability barriers for BRB according to the permeability
coefﬁcients20. The relatively apparent permeability ratio was
obtained by the equation:
Ratio Papp; A to B
 ¼ Papp; A=Papp; B: ð4Þ
where Ratio (Papp,A to B) represents the relatively apparent
permeability ratio of drug A and drug B, Papp, A and Papp, B,
respectively, represent the apparent permeability coefﬁcients of
drug A and drug B. Table 2 summarized the permeability values of
F–Tau and ﬂuorescein across ARPE-19 and hRMECs monolayer
cells. The permeability of F–Tau across the two monolayer cells
was both higher than that of ﬂuorescein, 7.72 versus 5.56 on
ARPE-19 and 10.67 versus 7.23 on hRMECs, and the Ratio (Papp,
F–Tau to ﬂuorescein) was up to 1.39 and 1.47, respectively. These
results suggested that F–Tau, the conjugate of ﬂuorescein by
conjugating taurine to ﬂuorescein, notably elevated the cell barrier
penetration of ﬂuorescein.
Several possible explanations for the increased penetration of
F–Tau can be considered. Firstly, molecular size cannot explain
these results because the molecular volume of ﬂuorescein is
smaller than that of F–Tau. Secondly, membrane solubility is
not a factor because ﬂuorescein is more lipid soluble than F–Tau.
Furthermore, F–Tau and ﬂuorescein could be seen to internalize to
the interior cell in the uptake experiments, suggesting that the
penetrating characteristics of F–Tau are relevant. Considering the
contradictory phenomena of low log P value and the high
penetration of F–Tau, we may reasonably conclude that the
transport of F–Tau is mediated via a speciﬁc transporter, and that
this transporter may improve the penetrability of ﬂuorescein to
retinal cells.3.6. Transport mechanisms of ﬂuorescein and F–Tau across
monolayers in vitro
After pre-incubation with 10 mmol/L taurine, F–Tau accumulation
was signiﬁcant (Po0.05), similar to that seen without pre-
incubation; Ratios (Papp, F–TauþTau to ﬂuorescein) of 1.40 and 1.84
were observed on ARPE-19 and hRMECs monolayers. But as
shown in Fig. 3 and Table 2, the transport of F–Tau in cells
previously incubated with free taurine did not show the inhibition,
but rather an increase in the pentration of ARPE-19 and hRMECs
monolayer cells; the resulting Papp, F–TauþTau to F–Tau values ranged
from 7.79 to 7.72 on ARPE-19 and 13.30 to 10.67 on hRMECs.
One possible answer for these unexpected results was that free
taurine, used as the competitive inhibitor, may have activated other
transport pathways to improve the penetrability of F–Tau as
Synthesis of taurine–ﬂuorescein conjugate and evaluation of its retina-targeted efﬁciency in vitro 453reported in other studies27,28. Identiﬁcation of such transporters
requires further studies29.4. Conclusions
There is an urgent need for the development of improved
treatments for many retina diseases. The BRB signiﬁcantly
impedes the delivery of many systemically-administered medica-
tions for treating the retina. In this study, we investigated an
effective retina-targeting ligand to increase the BRB permeability
of drugs. Since exogenous taurine is concentrated in the retina
where it functions as a neuroprotective agent, this compound was
chosen to evaluate its retina-targeting efﬁcacy. F–Tau, synthesized
by conjugating taurine to ﬂuorescein, was studied for this purpose.
The results indicated that the introduction of taurine could result in
an improvement of solubility, a reduction of log P and a prolonged
residence time of F–Tau on the cells compared with ﬂuorescein.
The transport studies also indicated that the introduction of taurine
exhibited signiﬁcantly strong transepithelial permeability across
the retinal cell barriers in vitro. Taurine may be a promising ligand
for the delivery of retina-targeted medications.Appendix A. Supplementary material
Supplementary data associated with this article can be found in the
online version at http://dx.doi.org/10.1016/j.apsb.2014.10.006.References
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